The latest
case study published in [Journal of
Guangzhou University of TCM, China. May 2004 - Vol.2,
N0.3] have shown that the combination of Phyllanthus
compound and lamivudine exerts a better effect in treating
chronic hepatitis B and is capable of reducing YMDD mutation,
delaying the occurrence of lamivudine-resistance virus
and prevent continuous in vivo replication of hepatitis
B virus.
Other Case Studies
K.T. Singam, K. A. Ong.
Efficacy of standardized extract of Phyllanthus niruri
, EPN 797 in inducing HBeAg clearance and seroconversion
of HBV infection: three case reports.
Zhang, JJ, Wang, HJ, Zhang, H. (GuangZhou
Province Hospital, Shandong)
Phyllanthus Compound Plus Lamivudine In Treatment Of 40
Cases Of Chronic Hepatitis B
The Chinese Study: A Randomised Controlled Trial
A Comparative
Study Of Phyllanthus Compound And Lamivudine In The Treatment
Of Chronic Hepatitis B
The Chinese Study: A Randomised Controlled Trial
Huang Zheng-chang, Zhu Bian-xian, Zheng Qi-jin, Yang Shu-lan,
Tan Bo, He Jin-yang, Zhu Yu-tong, Guo Xing-bo
(Tropical Medicine Institute, Guangzhou University of TCM,
Guangzhou 510405, China)
ABSTRACT
Objective: To investigate the therapeutic
effect of Phyllanthus compound (PC), lamivudine and the
combination of the above two drugs on chronic hepatitis
B.
Method: Ninety cases of chronic hepatitis
B were randomised to three groups: Group A (PC 2.6g, three
times a day), Group B (lamivudine 100mg, once a day) and
Group C (the combination of PC and lamivudine). Oral use
of the above drugs was continued for 52 weeks. Hepatic function
and serum contents of hepatitis B surface antigen (HBsAg),
hepatitis B e antigen (HBeAg), HBV-DNA and gene mutation
of YMDD (tyrosine-methionine-aspartic acid-aspartic acid)
were observed before and after treatment.
Result: The recovery rate of hepatic function
and HBeAg conversion rate were higher, rate of loss of HBV-DNA
was lower and YMDD mutation less in Group A than those in
Group B (P<0.05); In Group C, HBeAg conversion rate was
similar to that in Group A (P>0.05) but higher than that
in Group B (P<0.01). Loss of HBV-DNA was higher than
that in Group A and B, the recovery rate of hepatic function
was higher and YMDD mutation less than those in Group B
(P<0.05 or P<0.01).
Conclusion: The combination of PC and
lamivudine exerts a better effect in treating chronic hepatitis
B and is capable of reducing YMDD mutation, delaying the
occurrence of lamivudine-resistance virus and prevent continuous
in vivo replication of hepatitis B virus.
Efficacy
of standardized extract of Phyllanthus niruri , EPN 797
in inducing HBeAg clearance and seroconversion of HBV infection:
three case reports K.T. Singam
B.sc. MBBS [S’PORE], MCGP., DIP. STD./AIDS
K Singam And Associate Clinic, Sg. Pelek, Sepang, Selangor.
K. A. Ong
B. Pharm.[USM], Rph.
2Nova Laboratories Sdn. Bhd., Sg. Pelek, Sepang, Selangor.
ABSTRACT:
Active viral replication in hepatocytes is indicated by
the presence of hepatitis B e antigen (HBeAg) in serum.
HBeAg is thus a surrogate marker for the presence of hepatitis
B virus DNA. There are recent data that show the relationship
between the risk of developing hepatocellular carcinoma
(HCC) with the activity of the virus. There is a markedly
increased risk of developing HCC in those individuals with
chronic hepatitis B who are also e-antigen positive. We
describe three cases where patients with positivity of HBeAg
treated with the combination therapy of lamivudine 100mg
and EPN 797 1500mg daily or monotherapy with EPN 797 1500
mg daily alone for a duration of treatment ranged from 3
to 7 months, had achieved HBeAg clearance in all three cases
and seroconversion in 2 cases. Throughout the treatment
period, these three patients had normal ALT level. These
three cases suggested that the use EPN 797 alone or combination
with lamivudine might be useful in inducing HBeAg clearance
and seroconversion that could possibly reduce the risk of
developing HCC.
Phyllanthus
Compound Plus Lamivudine In Treatment Of 40 Cases Of Chronic
Hepatitis B The Chinese Study: A Randomised Controlled
Trial
Zhang, JJ, Wang, HJ, Zhang, H.
(GuangZhou Province Hospital, Shandong)
ABSTRACT
Objective: To evaluate the therapeutic
effect of Phyllanthus compound (PC) and lamivudine combination
in treating chronic hepatitis B.
Method: Seventy cases of chronic hepatitis
B were randomised to two groups: Treatment Group (PC 80ml,
twice a day and lamivudine 100mg, once a day), Control Group
(lamivudine 100mg, once a day). Oral use of the above drugs
was continued for 6 months. Subjects physical conditions,
symptoms, liver functions and serum contents of hepatitis
B surface antigen (HBsAg) and antibody (anti-HBs), hepatitis
B e antigen (HBeAg) and antibody (anti-HBe), hepatitis B
core antibody (anti-HBc) and HBV-DNA were observed before
and after 1, 2, 3, 4, 5, 6 month of treatment.
Result: Treatment Group shows significant
clinical improvement after 6 months compare to Control Group
(P<0.05). The total effectiveness was 92.5%, the recovery
rate of ALT, AST, A/G, SB were 70.0%, 80.5%, 81.3% and 77.3%.
The sero-conversion rate of HBsAg, HBeAg and HBV-DNA were
12.5%, 52.8% and 58.8%, significantly different compare
to the Control Group (P<0.05).
Conclusion: The combination of PC and
lamivudine can lead to a synergistic effect and exerts a
better result in treating chronic hepatitis B.
